How do you incorporate trastuzumab, pembrolizumab, and FOLFOX, as per KEYNOTE-811?

I have been thinking about this a lot recently, as the original study was based on treatment with 5FU/cisplatin or capecitabine/oxaliplatin, both of which were q3 week trials. It begs the question as to whether one should consider 5FU/cis over FOLFOX in HER2-positive patients with GEJ adenocarcinoma...

I agree with incorporating pembrolizumab but my experience with Q6 week pembro has been different from Q3 week with regard to AE's. I would be hesitant to make that leap to Q6 weeks.